Trastuzumab mediated T-cell response against HER-2/neu overexpressing esophageal adenocarcinoma depends on intact antigen processing machinery

PLoS ONE

Volumn 5, Issue 8, 2010, Pages

  Milano, Francesca ^a   Guarriera, Mirta ^a   Rygiel, Agnieszka M ^a   Krishnadath, Kausilia K ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; MEMBRANE PROTEIN; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 2; TRASTUZUMAB; UNCLASSIFIED DRUG; ABC TRANSPORTER; MONOCLONAL ANTIBODY; TAP2 PROTEIN, HUMAN;

ADULT; AGED; ANTIGEN PRESENTATION; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL INTERACTION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; ESOPHAGEAL ADENOCARCINOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MALE; MIXED LYMPHOCYTE REACTION; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; TUMOR CELL DESTRUCTION; ADENOCARCINOMA; CELL CULTURE; ESOPHAGUS TUMOR; GENE EXPRESSION; GENETICS; IMMUNOLOGY; MIDDLE AGED; T LYMPHOCYTE; TUMOR CELL LINE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGEN PRESENTATION; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; CELLS, CULTURED; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; RECEPTOR, ERBB-2; T-LYMPHOCYTES;

EID: 77957861323     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012424     Document Type: Article

References (39)

1. Hung MC, Lau YK (1999) Basic science of HER-2/neu: a review. Semin Oncol 26: 51-59.
2. Perez SA, Sotiropoulou PA, Sotiriadou NN, Mamalaki A, Gritzapis AD, et al. (2002) HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitroinduced specific CD4(+) T cell clones. Cancer Immunol Immunother 50: 615-624.
3. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792.
4. Murray JL, Gillogly ME, Przepiorka D, Brewer H, Ibrahim NK, et al. (2002) Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colonystimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res 8: 3407-3418.
5. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Kunz J, et al. (1993) Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum Pathol 24: 1127-1134.
6. Geddert H, Zeriouh M, Wolter M, Heise JW, Gabbert HE, et al. (2002) Gene amplification and protein overexpression of c-erb-b2 in Barrett carcinoma and its precursor lesions. Am J Clin Pathol 118: 60-66.
7. Walch A, Bink K, Gais P, Stangl S, Hutzler P, et al. (2000) Evaluation of c-erbB- 2 overexpression and Her-2/neu gene copy number heterogeneity in Barrett's adenocarcinoma. Anal Cell Pathol 20: 25-32.
8. Reichelt U, Duesedau P, Tsourlakis M, Quaas A, Link BC, et al. (2007) Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 20: 120-129.
9. Dahlberg PS, Jacobson BA, Dahal G, Fink JM, Kratzke RA, et al. (2004) ERBB2 amplifications in esophageal adenocarcinoma. Ann Thorac Surg 78: 1790-1800.
10. Gritzapis AD, Mahaira LG, Perez SA, Cacoullos NT, Papamichail M, et al. (2006) Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo. Cancer Res 66: 5452-5460.
11. Baxevanis CN, Sotiriadou NN, Gritzapis AD, Sotiropoulou PA, Perez SA, et al. (2006) Immunogenic HER-2/neu peptides as tumor vaccines. Cancer Immunol Immunother 55: 85-95.
12. Kono K, Takahashi A, Sugai H, Fujii H, Choudhury AR, et al. (2002) Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin Cancer Res 8: 3394-3400.
13. Mimura K, Kono K, Hanawa M, Kanzaki M, Nakao A, et al. (2005) Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clin Cancer Res 11: 4898-4904.
14. Kimura K, Sawada T, Komatsu M, Inoue M, Muguruma K, et al. (2006) Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine. Clin Cancer Res 12: 4925-4932.
15. Leyland-Jones B (2002) Trastuzumab: hopes and realities. Lancet Oncol 3: 137-144.
16. Tripathy D, Slamon DJ, Cobleigh M, Arnold A, Saleh M, et al. (2004) Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 22: 1063-1070.
17. Gamliel Z (2000) Incidence, epidemiology, and etiology of esophageal cancer. Chest Surg Clin N Am 10: 441-450.
18. Pera M (2003) Trends in incidence and prevalence of specialized intestinal metaplasia, barrett's esophagus, and adenocarcinoma of the gastroesophageal junction. World J Surg 27: 999-1008 discussion 1006-1008.
19. Donington JS, Miller DL, Allen MS, Deschamps C, Nichols FC, 3rd, et al. (2004) Preoperative chemoradiation therapy does not improve early survival after esophagectomy for patients with clinical stage III adenocarcinoma of the esophagus. Ann Thorac Surg 77: 1193-1198; discussion 1198-1199.
20. Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, et al. (1997) Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 337: 161-167.
21. Safran H, Dipetrillo T, Akerman P, Ng T, Evans D, et al. (2007) Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys 67: 405-409.
22. Kono K, Takahashi A, Ichihara F, Sugai H, Fujii H, et al. (2002) Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res 62: 5813-5817.
23. Clemenceau B, Gallot G, Vivien R, Gaschet J, Campone M, et al. (2006) Longterm preservation of antibody-dependent cellular cytotoxicity (ADCC) of natural killer cells amplified in vitro from the peripheral blood of breast cancer patients after chemotherapy. J Immunother 29: 53-60.
24. Kono K, Sato E, Naganuma H, Takahashi A, Mimura K, et al. (2004) Trastuzumab (Herceptin) enhances class I-restricted antigen presentation recognized by HER-2/neu-specific T cytotoxic lymphocytes. Clin Cancer Res 10: 2538-2544.
25. zum Buschenfelde CM, Hermann C, Schmidt B, Peschel C, Bernhard H (2002) Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res 62: 2244-2247.
26. Milano F, Rygiel AM, Buttar N, Bergman JJ, Sondermeijer C, et al. (2007) An ex vivo readout for evaluation of dendritic cell-induced autologous cytotoxic T lymphocyte responses against esophageal cancer. Cancer Immunol Immunother 56: 1967-1977.
27. Boonstra JJ, van Marion R, Beer DG, Lin L, Chaves P, et al. Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. J Natl Cancer Inst 102: 271-274.
28. Rygiel AM, van Baal JW, Milano F, Wang KK, ten Kate FJ, et al. (2007) Efficient automated assessment of genetic abnormalities detected by fluorescence in situ hybridization on brush cytology in a Barrett esophagus surveillance population. Cancer 109: 1980-1988.
29. Muller MR, Grunebach F, Kayser K, Vogel W, Nencioni A, et al. (2003) Expression of her-2/neu on acute lymphoblastic leukemias: implications for the development of immunotherapeutic approaches. Clin Cancer Res 9: 3448-3453.
30. Milano F, van Baal JW, Rygiel AM, Bergman JJ, Van Deventer SJ, et al. (2007) An improved protocol for generation of immuno-potent dendritic cells through direct electroporation of CD14+ monocytes. J Immunol Methods 321: 94-106.
31. Wu AH, Hall WA, Low WC (2004) Identification of HLA a*0201 glioblastoma multiforme cell lines for immunotherapy by PCR-SSP and DNA sequencing. J Neurooncol 66: 1-8.
32. Bubenik J (2004) MHC class I down-regulation: tumour escape from immune surveillance? (review). Int J Oncol 25: 487-491.
33. Mehta AM, Jordanova ES, Kenter GG, Ferrone S, Fleuren GJ (2008) Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother 57: 197-206.
34. Meissner M, Reichert TE, Kunkel M, Gooding W, Whiteside TL, et al. (2005) Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res 11: 2552-2560.
35. Hurwitz E, Stancovski I, Sela M, Yarden Y (1995) Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. Proc Natl Acad Sci U S A 92: 3353-3357.
36. Lopez-Albaitero A, Nayak JV, Ogino T, Machandia A, Gooding W, et al. (2006) Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol 176: 3402-3409.
37. Ritz U, Momburg F, Pilch H, Huber C, Maeurer MJ, et al. (2001) Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int J Oncol 19: 1211-1220.
38. Seliger B, Ritz U, Abele R, Bock M, Tampe R, et al. (2001) Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res 61: 8647-8650.
39. Seliger B (2008) Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol Immunother 57: 1719-1726.